Research and Markets: Dermatology Therapeutics Market to 2017 - Alopecia Market is Forecast to Decline Due to Patent Expiry of Finasteride in 2013

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8f5a37/dermatology_therap) has announced the addition of the "Dermatology Therapeutics Market to 2017 - Alopecia Market is Forecast to Decline Due to Patent Expiry of Finasteride in 2013 and Weak Pipeline" report to their offering.

“Dermatology Therapeutics Market to 2017 - Alopecia Market is Forecast to Decline Due to Patent Expiry of Finasteride in 2013 and Weak Pipeline”

GBI Research, the leading business intelligence provider, has released its latest research, Dermatology Therapeutics Market to 2017 - Alopecia Market is Forecast to decline Due to Patent Expiry of Finasteride in 2013 and Weak Pipeline. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global therapeutics market. The report analyzes the markets for dermatology therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. It provides treatment usage patterns, revenue, annual cost of treatment and forecasts to 2017 for the key geographies and leading therapeutic segments.

The report also provides competitive benchmarking for the leading companies and it analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

The Herpes Therapeutics Market has Low Unmet Need and a Weak Pipeline

Herpes (simplex and zoster) pipeline portfolio is weak with 26 molecules under research and development. Seven molecules are under Phase III clinical studies, while five molecules have first in class mechanism of action among all pipeline molecules. Occurrence of headache, nausea, dizziness and abdominal is another common problem among patient population that is being treated with present therapies. Hence there is high demand for synthesizing safer drugs.

The herpes therapeutics has strong market for some antivirals such as Zovirax (acyclovir), Famvir (famciclovir), Zostavax (Herpes Zoster Vaccine) and Valtrex (valacyclovir). These drugs contribute for more than $1.2 billion of global herpes therapeutics market. Large sector of the market is shared by generics that are having low prices which demands high first in class outputs from research and development side to strengthen the market.

Companies Mentioned:

• Centocor Ortho Biotech Inc
• Amgen
• Abbott Laboratories
• Merck & Co., Inc.
• Novartis AG
• GlaxoSmithKline plc.

For more information visit http://www.researchandmarkets.com/research/8f5a37/dermatology_therap